Cancer News and Research

Latest Cancer News and Research

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. A team of researchers, led by Alberto Bardelli, at the University of Turin Medical School, Italy, has now identified a way to help predict which patients will respond to such drugs.

27 Jul 2010

NCCN enters into collaboration to introduce Proventys CDS Oncology system

The National Comprehensive Cancer Network and Proventys, a leader in advanced decision support technologies, have entered into an exclusive collaboration to introduce the Proventys CDS Oncology system, a first-of-its-kind Web platform that arms oncologists with expert recommendations and evidence facilitating the delivery of high-quality, individualized patient care.

27 Jul 2010

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

For the third time in four months, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a research grant aimed at helping people infected with multidrug-resistant tuberculosis. Taken together, all three NIH grants total $8.57 million.

27 Jul 2010

Study on treatment needs of prostate cancer patients with low level PSA

Controversy has long existed over the benefit of the prostate specific antigen (PSA) test used to screen for the presence of prostate cancer, and there has been little study to document the risk profile of men who have a PSA level at or below what is considered 'normal.' New research published in the latest edition of Archives of Internal Medicine (Vol. 170, No. 14) by a team of investigators at The Cancer Institute of New Jersey (CINJ), further explores this population. The findings show that most men with prostate cancer who tested below the normal PSA level and had low-risk disease nevertheless underwent aggressive treatment. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

27 Jul 2010

Four research teams to study role of exercise in preventing, treating chronic diseases

Canadians will benefit from new insights into the link between physical activity and health as the Honourable Leona Aglukkaq, Minister of Health, today announced funding for four research teams through the Canadian Institutes of Health Research. These teams will study the effects of exercise on the body and its role in the prevention and treatment of chronic diseases including arthritis, breast cancer and heart disease.

27 Jul 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

Childhood cancer survival associated with high risk of abnormal cardiac function

Childhood cancer survival is associated with increased risk of long-term abnormalities in cardiac function, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jul 2010

Abviva to receive patent for its new Mammastatin technology

Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2.267.095 within 12 weeks

27 Jul 2010

Johns Hopkins scientist wins $2.5M NIH Director's Pioneer Award

A Johns Hopkins scientist who proposes to design and create an all-new series of novel drugs is one of 17 winners of a special grant known as a Director's Pioneer Award from the National Institutes of Health.

27 Jul 2010

Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CoaguChek® XS Pro system, a new point-of-care anticoagulation monitor with a built-in bar code reader that can automatically scan and capture operator and patient identification information.

From Roche Sequencing and Life Science 27 Jul 2010

UCLA Health System launches hand transplantation program

The UCLA Health System has launched the new UCLA Hand Transplantation Program, the first of its kind on the West Coast and only the fourth such center in the United States. The program will help those who have suffered the traumatic loss of a hand or forearm and allow them to regain function and improve their quality of life. Qualified candidates are now being sought for a clinical study of the procedure.

27 Jul 2010

CPC partners with CU School of Medicine on stem cell research

A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

26 Jul 2010

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.

26 Jul 2010

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

26 Jul 2010

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

Our system of long-term care does not provide adequate or coordinated human services and medical treatment for our growing aging population. … Thanks to a provision of the new health care law known as the Community Living Assistance Services and Supports program, tomorrow's continuum of care does not have to be so unforgiving. For the first time, a voluntary public insurance program will be available to help adults and families pay for long-term care services (Bruce Chernof, 7/23).

26 Jul 2010

Brainlab launches ExacTrac Infrared Monitoring device for patient positioning during radiation therapy

Brainlab announced the availability of ExacTrac® Infrared Monitoring, an add-on device to existing treatment machines for monitoring patient positioning during radiation therapy treatments, at the American Association of Physicists in Medicine (AAPM) Annual Meeting last week.

26 Jul 2010

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

Biovest International, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus standard-of-care.

26 Jul 2010

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc.. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a humanized antibody to hepatocyte growth factor (HGF).

26 Jul 2010

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

26 Jul 2010

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical Incorporated today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. The Vaxfectin® adjuvant substantially improved vaccine effectiveness. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection.

26 Jul 2010

Cancer News and Research

Latest Cancer News and Research

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

NCCN enters into collaboration to introduce Proventys CDS Oncology system

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

Study on treatment needs of prostate cancer patients with low level PSA

Four research teams to study role of exercise in preventing, treating chronic diseases

Abbot's innovative solutions to be highlighted at AACC

Childhood cancer survival associated with high risk of abnormal cardiac function

Abviva to receive patent for its new Mammastatin technology

Johns Hopkins scientist wins $2.5M NIH Director's Pioneer Award

Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor

UCLA Health System launches hand transplantation program

CPC partners with CU School of Medicine on stem cell research

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

Brainlab launches ExacTrac Infrared Monitoring device for patient positioning during radiation therapy

FDA grants Biovest's BiovaxID vaccine Orphan Drug Designation for mantle cell lymphoma

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in